Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ELI LILLY & Co Director's Dealing 2025

Aug 12, 2025

29745_dirs_2025-08-12_43ede4c5-3359-4ab3-b40f-934fca842f74.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ELI LILLY & Co (LLY)
CIK: 0000059478
Period of Report: 2025-08-12

Reporting Person: Skovronsky Daniel (EVP, CSO & Pres. LRL & LLY Imm)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-08-12 Common Stock P 1000 $634.405 Acquired 137660.112 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 72359 Indirect
Common Stock 747 Indirect
Common Stock 2510 Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $634.21 to $634.42, inclusive. The reporting person undertakes to provide to Eli Lilly and Company, any security holder of Eli Lilly and Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

F3: On March 10, 2025, the Reporting Person's spouse transferred 2,510 shares of Eli Lilly and Company common stock to a spousal lifetime access trust, of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and children are beneficiaries.